Table S1. Compound annual growth rate (GAGR) of publications from 2007 to September 2022

| Year | Number of publications | Cumulative total | GAGR  |
|------|------------------------|------------------|-------|
| 2007 | 1                      | 1                |       |
| 2008 | 0                      | 1                | 0     |
| 2009 | 0                      | 1                | 0     |
| 2010 | 0                      | 1                | 0     |
| 2011 | 1                      | 2                | 14.87%|
| 2012 | 3                      | 5                | 16.50%|
| 2013 | 3                      | 8                | 6.94% |
| 2014 | 5                      | 13               | 6.26% |
| 2015 | 10                     | 23               | 6.54% |
| 2016 | 17                     | 40               | 5.69% |
| 2017 | 21                     | 61               | 3.91% |
| 2018 | 33                     | 94               | 3.67% |
| 2019 | 25                     | 119              | 1.83% |
| 2020 | 44                     | 163              | 2.27% |
| 2021 | 43                     | 206              | 1.57% |
| 2022 | 42                     | 248              | 1.17% |

Table S2. Relative growth rate (RGR) and doubling time (DT) of publications from 2007 to September 2022

| Year | Number of publications | Cumulative total | RGR       | DT   |
|------|------------------------|------------------|-----------|------|
| 2007 | 1                      | 1                | 0         | 1.00 |
| 2008 | 0                      | 1                | 0         |      |
| 2009 | 0                      | 1                | 0         |      |
| 2010 | 0                      | 1                | 0         |      |
| 2011 | 1                      | 2                | 69.31%    | 1.00 |
| 2012 | 3                      | 5                | 91.63%    | 0.76 |
| 2013 | 3                      | 8                | 47.00%    | 1.47 |
| 2014 | 5                      | 13               | 48.55%    | 1.43 |
| 2015 | 10                     | 23               | 57.05%    | 1.21 |
| 2016 | 17                     | 40               | 55.34%    | 1.25 |
| 2017 | 21                     | 61               | 42.20%    | 1.64 |
| 2018 | 33                     | 94               | 43.24%    | 1.60 |
| 2019 | 25                     | 119              | 23.58%    | 2.94 |
| 2020 | 44                     | 163              | 31.46%    | 2.20 |
| 2021 | 43                     | 206              | 23.41%    | 2.96 |
| 2022 | 42                     | 248              | 18.56%    | 3.73 |
Table S3. Top 10 source journals for related publications

| Rank | Count | Sources Journal                          | IF 2022 | JCR |
|------|-------|-----------------------------------------|---------|-----|
| 1    | 22    | JOURNAL OF NEURO-ONCOLOGY               | 4.506   | Q2  |
| 2    | 15    | FRONTIERS IN ONCOLOGY                   | 5.738   | Q2  |
| 3    | 13    | CANCERS                                 | 6.575   | Q1  |
| 4    | 5     | CLINICAL JOURNAL OF ONCOLOGY NURSING    | 1.283   | Q4  |
| 5    | 5     | PHYSICS IN MEDICINE AND BIOLOGY         | 4.174   | Q2  |
| 6    | 5     | PLOS ONE                                | 3.572   | Q2  |
| 7    | 4     | AMERICAN JOURNAL OF CANCER RESEARCH     | 5.942   | Q2  |
| 8    | 4     | SCIENTIFIC REPORTS                      | 4.996   | Q2  |
| 9    | 3     | BIOMEDICINE & PHARMACOTHERAPY           | 7.419   | Q1  |
| 10   | 3     | CANCER MEDICINE                         | 4.711   | Q2  |

Table S4. Top 10 keywords for related publications

| Rank | Count | Centrality | Keywords                        |
|------|-------|------------|---------------------------------|
| 1    | 156   | 0.01       | glioblastoma                    |
| 2    | 152   | 0          | tumor treating field            |
| 3    | 134   | 0.03       | temozolomide                    |
| 4    | 48    | 0.12       | randomized phase iii            |
| 5    | 46    | 0.13       | brain                           |
| 6    | 46    | 0.03       | survival                        |
| 7    | 44    | 0.03       | cancer                          |
| 8    | 42    | 0.03       | trial                           |
| 9    | 42    | 0.49       | alternating electric field      |
| 10   | 36    | 0.07       | radiotherapy                    |